Navigation Links
Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems
Date:8/9/2011

enue to be between $520 million and $550 million
  • Reported (GAAP) diluted earnings per share to be between $2.22 and $2.32
  • Adjusted diluted earnings per share to be between $4.55 and $4.65

  • The company's 2011 guidance is based on certain assumptions including:

  • Adjusted gross margin of between 69% and 71%
  • Adjusted effective tax rate of approximately 28%
  • Weighted average number of common shares outstanding of 123 million shares for the year ended December 31, 2011; and
  • No generic competition for Voltaren Gel in 2011

  • Selected Operating HighlightsOpana® ER Complete ResponseOn June 23, 2011, Endo Pharmaceuticals announced that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of Opana ER has been accepted.  The new formulation was developed in partnership with Grunenthal GmbH and is designed to provide some resistance to certain types of product manipulation.  FDA has set a Prescription Drug User Fee Act (PDUFA) date of Dec. 13, 2011.

    Completion of Acquisition of American Medical SystemsOn June 17, 2011, Endo Pharmaceuticals acquired American Medical Systems, Inc. (AMS), for approximately $2.9 billion. AMS brings Endo scale in its device and services business segment, and the combination of AMS with Endo's existing platform will provide additional cost-effective solutions across the entire urology spectrum.  It is expected that the combined company will deliver more comprehensive healthcare solutions across its diversified business in branded pharmaceuticals, generics, and devices and services in key therapeutic areas including pain and urology.

    Pricing of Private Offering of Senior Notes and 2011 Credit FacilityOn June 3, 2011, Endo Pharmaceuticals announced that it priced $500 million aggregate prin
    '/>"/>

    SOURCE Endo Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder and ... a scientific poster describing an innovative diagnostic procedure for ... Shedding New Light on Disease (SPEC) conference in Krakow, ... Treado,s poster entitled, "Development of in vitro Diagnostics for ... be discussed during the conference poster session on Tuesday, ...
    (Date:8/19/2014)... -- Tokyo-based Atonarp Inc. announced today $8 million in ... Riverwood Ventures with participation from other co-investors.  The ... technology platform, which will enable a broad range ... & gas and healthcare industries for its initial ... with Atonarp in pursuing the commercialization of its ...
    (Date:8/19/2014)... – a provider-led accelerator that puts the power of ... ­– announces Sutter Health, a not-for-profit health system in ... recent addition to the AVIA Innovator Network. ... focused helping patients navigate the healthcare system and enable ... so they work as a larger team for each ...
    Breaking Medicine Technology:ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
    ... Md., Oct  27, 2011 Neuralstem, Inc. (NYSE Amex: ... in the ongoing safety trial to test its neuroregenerative small ... (MDD).  Phase Ia tested the drug in healthy volunteers for ... commence later this year, will test the safety and tolerability ...
    ... Oct. 27, 2011 Herborium Group, Inc., ... company, announced the following update today. ... stated: "These are truly exciting times for our Company. ... Bulletin Board exchange by maintaining Herborium, Current Information ...
    Cached Medicine Technology:Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 2Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 3Herborium Group Shareholders Update 2Herborium Group Shareholders Update 3
    (Date:8/20/2014)... This agreement will allow storageFOUNDRY ... networking, high availability cloud enablement, service, and elastic ... allowing OPEN-V to sell storageFOUNDRY’s expanding Nautilus line ... with OPEN-V on this distribution agreement of our ... channels at storageFOUNDRY. "Nautilus is a massively scalable, ...
    (Date:8/19/2014)... well-known bamboo product manufacturer and retailer, has unveiled its new ... excited to reveal the new items, and it has decided ... every customer can get a discounted price, up to 30 ... , The company’s deckings are made of the finest quality, ... are perfect for a dining room, living room, kitchen, foyer, ...
    (Date:8/19/2014)... Crosley Law Firm, PC has reached a confidential ... Star Bakery for an undisclosed amount. The two claimants, Pete ... of 2011, respectively. The injuries were caused by two different ... to the left hand of each man. , At the ... short-staffed, having lost 200 of its, 500 workers in connection ...
    (Date:8/19/2014)... an outstanding company in the garment industry, has unveiled its ... to this, the company has also launched a big sale ... at low rates, up to 30 percent off. , ... bohemian outfits are available in many colours, including green, blush, ... quality clothes, reasonable prices and sincere service, the company has ...
    (Date:8/19/2014)... the brain involved in multitasking and ways to train ... the IUGM Institut universitaire de griatrie de Montral and ... to better predict the effectiveness of this training. Cooking ... the Web, or driving while listening to a radio ... our daily lives. Unfortunately, it decreases with age, which ...
    Breaking Medicine News(10 mins):Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Promotional Bamboo Deckings from Well-known Online Supplier BambooIndustry.com 2Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:Targeted brain training may help you multitask better 2
    ... have found out why women who have a baby when ... breast cancer. They have identified a substance produced naturally in ... pregnancy trigger the changes in the breast tissue of young ... a pill that could protect against breast cancer. ...
    ... franchisee for US based Medicine Shoppe International, with operations in ... list of its target for operations in the country. According ... expand its franchisee operations from the present 19 outlets to ... decided to put on hold the commencing of operations in ...
    ... Common childhood vaccinations, including newer ones such as those ... diabetes. The conclusion came from a look at 768 ... had juvenile diabetes. Those who had been vaccinated against ... no more likely to have developed diabetes than those ...
    ... hormone production may help explain why obese people who carry ... a high risk of heart disease and other health problems. ... and its complications. // ,It is no news ... heart disease and diabetes, but where these extra pounds accumulate ...
    ... some time that a wide range of influenza viruses circulate in ... humans. These are two subtypes of the influenza A virus known ... was reported in Hong Kong in mid-May . ,The ... six people and infect 12 others in a small but densely ...
    ... may not only an effective treatment for malaria, the ... be similar to the mechanism they use to ... these findings at the 50th Annual Meeting of the ... ,The compounds called disulfides, occur naturally in garlic, ...
    Cached Medicine News:
    ... Tips are available as both regular and ... by gamma-rays for more efficient sterilization and ... specifying the date of irradiation. Sterilized Diamond ... to autoclave. SterilPack Diamond Tips are wrapped ...
    This large 1000 L tip makes pipetting fragile cells, genomic DNA, and viscous samples easy. Perfect for cell culture laboratories....
    This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
    Conducting disposable filter-tips....
    Medicine Products: